Ӣ�������������������ƶ�ͯ�����ط��Թؽ����ٴ������о�

Clinical observation on infliximab and etanercept in the treatment of juvenile idiopathic arthritis.

????Objective To observe and evaluate the clinical effect and adverse effects of the infliximab and etanercept in treating patients with juvenile idiopathic arthritis ??JIA??.Methods There were 26 patients of JIA treated with anti-TNF therapy from June 2008 to December 2011.All patients were divided into two groups?? including those treated with in?iximab??11 patients?? and those with etanercept??15 patients??.We assessed clinical effects by DAS28??inactive disease standards and clinical remission??CRM/CR???? evaluating adverse reactions of two drugs as well.Results After a follow up of 3 to 31 months??the clinical symptoms and laboratory indexes of two groups were all improved.We have found statistical differences in CRP of infliximab at the beginning of therapy and after 3 months??in ESR of etanercept at the beginning of therapy and after 6 months??in swollen joint counts of etanercept at the beginning of therapy and after 3??12months??P??0.05????in the numbers of tender joints ??or pain with activity?? of etanercept at the beginning of therapy and after 3??6 months.Our study also showed statistically signi?cant differences in DAS28 values at the beginning of therapy and after 3??6 months in etanercept??and at the beginning of therapy and after 3 months in infliximab.There was obvious decrease of DAS28 values in etanercept compared with infliximab in the treatment of 3??6 months??but infliximab group much lower than etanercept one in 12 months.We found no signi?cant differences in short term clinical effect between the two drugs??P??0.05??.Except rushes and pain caused by injection??there were no other side effects in the two groups.Conclusion Both in?iximab and etanercept can reduce DAS28 values and improve joint function in patients with JIA.We find no signi?cant differences in the responses??remissions or adverse effects between both drugs in the short term.There are no serious adverse reactions in both groups.